Wall Street analysts see a 50.91% upside in Terns Pharmaceuticals (TERN): Can the stock really move this high?
Wall Street analysts project a 50.91% upside for Terns Pharmaceuticals (TERN). This article examines the stock's recent performance, analyst ratings, and factors that could influence its future price movement. Investors are interested if the company can reach this high target.
Wall Street analysts see a 50.91% upside in Terns Pharmaceuticals (TERN): Can the stock really move this high?
This article analyzes the potential upside for Terns Pharmaceuticals (TERN) as predicted by Wall Street analysts. With an average price target suggesting a 50.91% increase, the report will likely delve into the factors contributing to this optimistic forecast. It aims to assess whether the stock can genuinely achieve such a significant surge based on current market conditions and company performance.
Leerink Partners Begins Coverage on Terns Pharmaceuticals (NASDAQ:TERN)
Leerink Partners initiated coverage on Terns Pharmaceuticals (NASDAQ:TERN) with an "outperform" rating and a $58.00 price target, suggesting a 53.7% upside. The broader analyst consensus for TERN stock is a "Moderate Buy" with an average price target of $55.80. Notable insider selling from CEO Amy Burroughs and other insiders has been observed, with a total of 141,243 shares worth $5.31 million sold in the last 90 days.
Leerink Partners initiates Terns Pharmaceuticals stock with Outperform rating By Investing.com
Leerink Partners has initiated coverage on Terns Pharmaceuticals (NASDAQ:TERN) with an Outperform rating and a $58.00 price target, citing potential upside of 61%. The firm highlights TERN-701, an investigational drug for chronic myeloid leukemia, as a significant value driver with a potential $4.8 billion opportunity in the frontline setting. This comes after Terns Pharmaceuticals raised $747.5 million through a public offering and amended a license agreement for TERN-701.
Leerink Partners initiates Terns Pharmaceuticals stock with Outperform rating
Leerink Partners has initiated coverage on Terns Pharmaceuticals (NASDAQ:TERN) with an Outperform rating and a price target of $58.00, citing the potential of its drug candidate TERN-701 for chronic myeloid leukemia (CML). The drug, which is a next-generation allosteric BCR::ABL1 inhibitor, shows promise with early Phase 1 data suggesting a best-in-class profile and a clean safety record. Other recent developments include a successful public offering and strong analyst interest, with some firms setting even higher price targets.
Wall Street Analysts See a 50.91% Upside in Terns Pharmaceuticals (TERN): Can the Stock Really Move This High?
Wall Street analysts project a 50.91% upside potential for Terns Pharmaceuticals (TERN), with a mean price target of $58.13. Despite some skepticism regarding the reliability of price targets, the company's strong earnings estimate revisions and a Zacks Rank #2 (Buy) suggest a potential for solid upside. Investors are advised to use price targets as a starting point for further research, rather than the sole basis for investment decisions.
A Look At Terns Pharmaceuticals (TERN) Valuation After Expanded TERN-701 Rights And Positive Trial Update
Terns Pharmaceuticals (TERN) is under scrutiny after revising its agreement for TERN-701 and releasing positive interim Phase 1 data, which has led to a significant share price increase. Despite this, the company's valuation, evidenced by a Price-to-Book ratio of 14.1x, suggests it is overvalued compared to industry and peer averages, given its early-stage pipeline and current unprofitability. Investors are paying a premium for its future potential, but this valuation could be challenged by clinical setbacks or continued losses.
A Look At Terns Pharmaceuticals (TERN) Valuation After Expanded TERN-701 Rights And Positive Trial Update
Terns Pharmaceuticals (TERN) has seen a sharp increase in its share price following revised agreement for TERN-701 and positive interim Phase 1 data. Despite this, the company trades at a significantly higher Price-to-Book ratio (14.1x) compared to industry and peer averages, indicating investors are paying a premium for its early-stage oncology and obesity programs. The article suggests that while the clinical news is positive, investors should consider the early stage of the pipeline and the company's unprofitability.
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)
Terns Pharmaceuticals announced that it granted equity inducement awards to two new employees on February 1, 2026, under its 2022 Employment Inducement Award Plan. These awards, consisting of options to purchase 113,500 shares of common stock at an exercise price of $34.60, were approved by the Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4). The grants serve as a material inducement for their employment and vest over four years.
Terns Pharmaceuticals Reports Inducement Grants To New Employees Under Nasdaq Listing Rule
Terns Pharmaceuticals announced that it has made inducement grants to new employees in accordance with Nasdaq Listing Rule 5635(c)(4). The grants are part of the company's efforts to attract and retain talent. This notification was reported by Reuters via Refinitiv.
Terns Pharmaceuticals (TERN) Eyes Expansion Beyond China Amid Strong Analyst Sentiment
Terns Pharmaceuticals (TERN) has amended its license agreement for TERN-701, converting a non-exclusive license into an exclusive, royalty-bearing worldwide license outside of the Hansoh Territory, strengthening its commercialization rights. This strategic move, along with a significant price target increase from Citizens and an 'Outperform' rating, is driven by positive interim Phase 1 CARDINAL ASH update featuring TERN-701’s strong profile. The company focuses on developing therapies for NASH, oncology, and chronic liver disease, utilizing small molecules and combination therapies.
Terns Pharmaceuticals (TERN) Eyes Expansion Beyond China Amid Strong Analyst Sentiment
Terns Pharmaceuticals (TERN) has strategically amended its license agreement with Hansoh, gaining exclusive, sublicensable, royalty-bearing worldwide rights for therapeutic products with TERN-701 as the sole active ingredient, excluding the Hansoh Territory. This move strengthens its commercialization rights outside of China, Hong Kong, and Macau. The revision follows a bullish update from Citizens, which raised TERN's price target to $57 and reiterated an ‘Outperform’ rating, citing TERN-701's strong interim Phase 1 CARDINAL ASH results.
Terns Pharmaceuticals, Inc. (NASDAQ:TERN) Receives Average Recommendation of "Moderate Buy" from Analysts
Terns Pharmaceuticals (NASDAQ:TERN) has received a "Moderate Buy" average recommendation from thirteen analysts, with an average one-year target price of $55.56. Recent analyst upgrades and increased price targets from firms like HC Wainwright, Oppenheimer, and UBS highlight positive sentiment. However, insider activity shows sales of 165,763 shares totaling $5.75 million in the last quarter, including a significant sale by CEO Amy L. Burroughs.
Novo climbs higher on ‘strong’ Wegovy pill launch; Terns tweaks leukemia drug deal
Novo Nordisk's oral Wegovy launch shows "very strong" early prescription numbers, surpassing expectations and not cannibalizing injectable sales. Terns Pharmaceuticals amended its leukemia drug deal with Hansoh Pharmaceutical, gaining licensing flexibility for TERN-701, aimed at facilitating new partnerships. Additionally, Corcept Therapeutics' relacorilant extended survival in an ovarian cancer trial, and BioMérieux acquired the remaining stake in Accellix to enhance its cell therapy quality control offerings.
Terns Pharmaceuticals amends license agreement with Hansoh for TERN-701 rights
Terns Pharmaceuticals has amended its license agreement with Hansoh (Shanghai) Healthtech Co., Ltd. for TERN-701, a therapeutic product for oncology indications. The new amendment grants Terns Pharmaceuticals exclusive worldwide rights, excluding the Hansoh Territory, to patents and applications related to TERN-701, replacing a previous non-exclusive license. Terns will pay a one-time upfront fee of $1 million and tiered royalties on net sales, reinforcing its strong financial position and recent positive clinical and financial developments.
Terns Pharmaceuticals amends license agreement with Hansoh for TERN-701 rights
Terns Pharmaceuticals has amended its license agreement with Hansoh, gaining exclusive worldwide rights (excluding Hansoh's original territory) to TERN-701 for a $1 million upfront fee and tiered royalties. This update follows Terns' significant financial successes, including a $747.5 million public offering, and positive Phase I clinical trial results for TERN-701 in treating chronic myeloid leukemia, which have led to favorable analyst ratings. The company's stock has surged 685% over the past year, and it maintains a strong financial position, evidenced by a high current ratio.
Assessing Terns Pharmaceuticals (TERN) Valuation After New TERN-701 Data And Capital Raise
Terns Pharmaceuticals (TERN) is under scrutiny following new Phase 1 data for TERN-701, recent conference exposure, and a significant equity raise. Despite a large 1-year total shareholder return, the stock has experienced short-term volatility. The company, currently loss-making with a P/B ratio of 14x, is considered overvalued compared to industry peers, suggesting its current price heavily relies on future pipeline potential rather than existing financials.
Terns Pharmaceuticals CEO Burroughs sells $2.5 million in stock
Terns Pharmaceuticals CEO Amy L. Burroughs sold approximately $2.5 million worth of common stock on January 15, 2026, after exercising options to acquire the same number of shares at a significantly lower price. Despite the sale, which was executed under a pre-arranged trading plan, Burroughs increased her direct and indirect holdings in the company. The stock has seen a substantial increase over the past year and analysts have set price targets significantly higher than its current trading price, following positive clinical trial data and a successful public offering.
Terns Pharmaceuticals CEO Burroughs sells $2.5 million in stock By Investing.com
Terns Pharmaceuticals CEO Amy L. Burroughs sold 68,749 shares of common stock for approximately $2.5 million on January 15, 2026, executed under a pre-arranged trading plan. Concurrently, she exercised options to acquire the same number of shares and was granted additional shares and options. The company's stock has seen significant growth, showing a 721% return over the past year, and recently closed a public offering raising $747.5 million, with analysts reiterating positive ratings.
Wall Street forecasts 42.31% upside to Terns Pharmaceuticals, Inc. (TERN)
The article states that Wall Street analysts are forecasting a 42.31% upside for Terns Pharmaceuticals, Inc. (TERN). This indicates a strong positive outlook from financial experts regarding the company's future stock performance.
How Investors Are Reacting To Terns Pharmaceuticals (TERN) Promising TERN-701 Phase 1 CARDINAL Data
Terns Pharmaceuticals (TERN) recently presented promising interim Phase 1 CARDINAL data for its drug, TERN-701, which is being called potentially "best-in-class." This data reinforces the company's investment narrative, largely centered on TERN-701, and could influence future Phase 2/3 planning. Investors are closely watching for further data given the company's reliance on this single asset and recent share price volatility.
How Investors Are Reacting To Terns Pharmaceuticals (TERN) Promising TERN-701 Phase 1 CARDINAL Data
Terns Pharmaceuticals recently presented promising interim Phase 1 CARDINAL ASH data for TERN-701, which suggests a potentially best-in-class profile and encouraging deep molecular responses. This data strengthens the investment narrative around TERN-701 as the company's core asset, shifting focus toward clinical execution ahead of the larger ASH 2025 dataset and Phase 2/3 planning. However, investors face high expectations and significant share price volatility, underscoring the importance of future data readouts.
Wall Street Forecasts 42.31% Upside To Terns Pharmaceuticals, Inc. (TERN)
Wall Street analysts are forecasting a significant upside for Terns Pharmaceuticals, Inc. (NASDAQ: TERN), with a projected 42.31% increase based on a one-year average share price target of $53.75. This bullish outlook follows encouraging Phase 1 study data for TERN-701, its lead program for chronic myeloid leukemia, which analysts like Truist Financial and Mizuho Securities believe has immense potential. The company's shares have already surged over 300% in the past three months, and CEO Amy Burroughs aims for pivotal trials by the end of 2026.
Wall Street Forecasts 42.31% Upside To Terns Pharmaceuticals, Inc. (TERN)
Wall Street analysts are forecasting a 42.31% upside for Terns Pharmaceuticals, Inc. (TERN), driven by promising Phase 1 study data for TERN-701, a lead program for chronic myeloid leukemia (CML). Both Truist Financial and Mizuho Securities reiterated "Buy" and "Outperform" ratings respectively, citing the drug's potential as a "best-in-disease treatment" and its strong efficacy and safety profile. The company's shares have surged over 300% in the last three months, with analysts projecting further growth based on an average share price target of $53.75.
Citizens Maintains An Outperform Rating On Terns Pharmaceuticals, Inc. (TERN)
Citizens has maintained an Outperform rating on Terns Pharmaceuticals, Inc. (TERN) and raised its price target to $57 from $35, citing strong Phase 1 CARDINAL ASH data for TERN-701. The company's TERN-701 drug showed potential for a best-in-class profile for CML treatment. Despite promising clinical data and sufficient cash to cover operating costs until 2028, the stock saw a slight decline of 3.07% as of January 6, 2026.
J.P. Morgan: Terns Looks To Take Flight With TERN-701 In 2026
J.P. Morgan predicts that Terns Pharmaceuticals will launch its drug candidate TERN-701 in 2026. The article highlights this forecast regarding Terns Pharmaceuticals and its oncology drug. It also lists related companies and additional topics discussed at the J.P. Morgan conference.
Will Fast Track TERN-701 Status and $747.5 Million Raise Change Terns Pharmaceuticals' (TERN) Narrative
Terns Pharmaceuticals recently received FDA Fast Track designation for TERN-701, its chronic myeloid leukemia therapy, and completed a $747.5 million public offering, extending its cash runway into 2031. While these developments reduce financing pressure and support the CARDINAL trial's progress, the company's valuation remains a point of discussion among investors due to a lack of revenue, insider sales, and a high price-to-book multiple. The article suggests that Terns Pharmaceuticals may still be trading beyond its estimated value, encouraging investors to conduct their own robust analysis.
Assessing Terns Pharmaceuticals (TERN) Valuation After Recent Share Price Swings And Elevated Price To Book Ratio
Terns Pharmaceuticals (TERN) has seen significant share price volatility recently, with a dramatic increase over three months but a decline in the last 30 days. Despite being a loss-making clinical-stage company, its Price-to-Book ratio of 14.5x is much higher than the industry average, suggesting the market is valuing its clinical pipeline and future potential very highly. Investors are cautioned to consider clinical trial risks and future financing needs against this elevated valuation.
Terns Pharmaceuticals (NASDAQ:TERN) Trading Down 6.3% - Here's Why
Terns Pharmaceuticals (NASDAQ:TERN) saw its share price drop by 6.3% amidst lower trading volume, closing at $35.3750. This occurred despite several analysts raising their price targets for the company in recent weeks, with an average target price of $55.56 and a "Moderate Buy" consensus rating. However, insider selling, including a significant reduction in CEO Amy L. Burroughs' stake, and limited insider ownership paint a more cautious picture.
Assessing Terns Pharmaceuticals (TERN) Valuation After Recent Share Price Swings And Elevated Price To Book Ratio
Terns Pharmaceuticals (TERN) has seen significant share price volatility, with a strong 90-day return despite a recent 30-day decline. The company is currently trading at a high Price to Book (P/B) ratio of 14.5x, significantly above the industry average, which suggests the market is placing a high value on its clinical pipeline despite its loss-making status. Investors are prompted to consider whether this valuation is justified or if the stock is overvalued given potential clinical trial risks and financing needs.
Tern Pharmaceuticals (TERN) soars 630% on CML treatment best-in-class potential
Tern Pharmaceuticals (TERN) shares surged by 630% due to positive clinical trial results for its chronic myeloid leukemia (CML) drug, TERN-701. Preclinical data indicates that TERN-701 could be a best-in-class treatment, significantly improving upon existing therapies like Novartis's Tasigna while potentially reducing severe side effects. The company plans to initiate Phase I/II clinical trials in Australia later this year.
Terns Pharmaceuticals (TERN) price target increased by 75.91% to 54.63
The article states that the price target for Terns Pharmaceuticals (TERN) has been increased significantly by 75.91% to a new target of 54.63. No further details are provided in the snippet.
Will Fast Track TERN-701 Status and $747.5 Million Raise Change Terns Pharmaceuticals' (TERN) Narrative
Terns Pharmaceuticals recently reported positive Phase 1 data and strong enrollment for its TERN-701 CARDINAL trial, alongside achieving US FDA Fast Track designation for the therapy. An upsized public offering raised $747.5 million, extending the company's cash runway into 2031 and alleviating immediate financing concerns. However, despite these positive developments, the company's valuation remains under scrutiny due to its pre-revenue status, insider share sales, and a rich price-to-book multiple.
Terns Pharmaceuticals to Highlight 2026 Priorities and Program Milestones at the 44th Annual J.P. Morgan Healthcare Conference
Terns Pharmaceuticals will present its 2026 priorities and program milestones at the 44th Annual J.P. Morgan Healthcare Conference. Key highlights include advancing TERN-701 for CML, which received U.S. FDA Fast Track designation, and outlining a clinical development plan targeting pivotal trials by late 2026/early 2027. The company boasts a strong financial position with approximately $1.0 billion in cash, providing a runway into 2031.
Terns Pharmaceuticals CEO Burroughs sells $2.7m in shares By Investing.com
Terns Pharmaceuticals CEO Amy L. Burroughs sold 71,339 shares of common stock for over $2.7 million on January 5, 2026, after exercising options for 171,551 shares. Following these transactions, Burroughs directly owns 138,976 shares and indirectly owns 8,319 shares. The company recently completed a $747.5 million public offering and received positive analyst ratings following promising clinical trial data for its therapies.
Terns Pharmaceuticals CEO Burroughs sells $2.7m in shares
Amy L. Burroughs, CEO of Terns Pharmaceuticals (NASDAQ:TERN), sold 71,339 shares for over $2.7 million on January 5, 2026, after exercising options for 171,551 shares. Post-transaction, Burroughs directly owns 138,976 shares and indirectly 8,319 shares. This follows a successful $747.5 million public offering and positive analyst responses to promising clinical updates.
Terns Pharmaceuticals CMO Kuriakose sells $44,552 in stock
Emil Kuriakose, Chief Medical Officer of Terns Pharmaceuticals (NASDAQ:TERN), sold 1,155 shares of common stock for approximately $44,552 on January 2, 2026. These sales were made to cover taxes related to restricted stock units rather than discretionary trades. Terns Pharmaceuticals has demonstrated significant market momentum with a 580% return over the past year and recently closed a public offering raising $747.5 million, while also presenting promising data for its TERN-701 therapy for CML.
Terns Pharmaceuticals, Inc. (NASDAQ:TERN) Receives Average Recommendation of "Moderate Buy" from Brokerages
Terns Pharmaceuticals, Inc. (NASDAQ:TERN) has received a "Moderate Buy" consensus rating from thirteen analysts, with an average 12-month target price of $55.56. The company recently reported a quarterly loss of ($0.27) per share, beating estimates, and its shares opened at $40.59 with a market cap of $3.66 billion. Institutional investors hold approximately 98.26% of the stock, while insiders have recently sold some shares.
With 53% Institutional Ownership, Terns Pharmaceuticals, Inc. (NASDAQ:TERN) Is a Favorite Amongst the Big Guns
Terns Pharmaceuticals, Inc. (NASDAQ:TERN) is significantly owned by institutions, holding 53% of its shares, with 10 investors collectively owning 52%. This substantial institutional presence suggests that their trading decisions can highly influence the stock's price. Hedge funds and private equity firms also hold considerable stakes, indicating potential for active engagement and a focus on value creation, while individual investors hold a 21% share.
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)
Terns Pharmaceuticals, Inc. announced equity inducement awards to two new employees under its 2022 Employment Inducement Award Plan, effective January 1, 2026. The awards, approved by the Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4), include options to purchase 312,000 shares of common stock with an exercise price of $40.40, vesting over four years. Terns Pharmaceuticals is a clinical-stage oncology company focusing on innovative medicines like TERN-701 for chronic myeloid leukemia.
Tern Pharmaceuticals (TERN) Soars 630% on CML Treatment Best-in-Class Potential
Terns Pharmaceuticals (NASDAQ:TERN) experienced a significant 629.64% increase in 2025 due to positive clinical trial results for its chronic myeloid leukemia (CML) therapy candidate, TERN-701. The drug showed promising improvements in patients and a high major molecular response rate at higher doses, leading the company to raise $747.5 million for its development and future launch. The article also suggests that certain AI stocks might offer even higher returns.
Tern Pharmaceuticals (TERN) Soars 630% on CML Treatment Best-in-Class Potential
Terns Pharmaceuticals (TERN) experienced a significant 630% surge in 2025, driven by promising clinical trial results for TERN-701, a potential best-in-class treatment for chronic myeloid leukemia (CML). The therapy showed a 64% improvement in patients and a 74% major molecular response rate at higher doses, leading to a successful $747.5 million fundraising for its development and future launch. The article also suggests that some AI stocks may offer even greater potential returns.
Meet the 10 Market Stars Behind Millionaire-Making in 2025
Terns Pharmaceuticals Inc. (NASDAQ:TERN) saw a significant climb in 2025, driven by positive clinical trial results for its chronic myeloid leukemia (CML) therapy candidate, TERN-701. The drug demonstrated considerable improvement in patients and a high major molecular response rate at higher doses, leading to a successful capital raise of $747.5 million for its development, manufacturing, and future commercial launch.
Terns Pharmaceuticals stock slides today, testing the $40 level after December share sale
Terns Pharmaceuticals (TERN) stock declined 2.8% to $40.34, hovering around the $40 mark, which was the price of its recent upsized equity offering. The pullback comes after the company's December financing and a trial update for TERN-701, focusing investor attention on the biotech's ability to advance early leukemia data into larger studies and its extended cash runway into 2031. No immediate company-specific news explained the decline, with market participants attributing it to a broader sector pullback and post-fundraising positioning.
Exchange Traded Concepts LLC Has $912,000 Position in Terns Pharmaceuticals, Inc. $TERN
Exchange Traded Concepts LLC has significantly reduced its stake in Terns Pharmaceuticals, Inc. (TERN) by 46.7%, now holding 121,455 shares valued at $912,000. Despite this, institutional investors collectively own 98.26% of the company. Wall Street analysts are largely bullish on Terns, with a "Moderate Buy" consensus rating and an average price target of $55.56, following the company's recent beat on quarterly EPS estimates.
Terns Pharmaceuticals (TERN) climbs 53% on stellar leukemia treatment trial
Terns Pharmaceuticals (TERN) shares soared over 53% after presenting positive interim data for its leukemia treatment, TERN-701, at the American Society of Hematology Annual Meeting. The trial showed significant clinical responses and an encouraging safety profile in patients with chronic myeloid leukemia (CML), suggesting a promising new option for CML patients.
Terns Pharmaceuticals (TERN) Is Down 7.7% After Strong TERN-701 Phase 1 Data - Has The Bull Case Changed?
Terns Pharmaceuticals recently announced strong Phase 1 results for TERN-701, a chronic myeloid leukemia candidate, showing high response rates and supporting its advancement to Phase 2. While this data strengthens Terns' investment narrative by highlighting TERN-701 as a key catalyst, the company's valuation, lack of revenue, widening losses, and ongoing dilution remain significant concerns for investors. The stock's recent performance reflects both optimism from the clinical data and caution regarding the company's financial health and dependency on a single lead asset.
Terns Pharmaceuticals (TERN) Is Down 7.7% After Strong TERN-701 Phase 1 Data - Has The Bull Case Changed?
Terns Pharmaceuticals (TERN) recently announced positive Phase 1 results for its chronic myeloid leukemia candidate TERN-701, showing strong molecular response rates and supporting its advancement to Phase 2 trials. Despite this promising data, the stock experienced a 7.7% decline, raising questions about whether the positive clinical outcome was already priced into the stock. The company faces ongoing challenges with its premium valuation, cash burn, and recurrent equity raises, which continue to be central concerns for investors, especially given its reliance on a single lead asset.
Terns Pharmaceuticals (TERN) price target increased by 75.91% to 54.63
This article reports a significant increase in the price target for Terns Pharmaceuticals (TERN), with an adjustment of 75.91% to $54.63. The article is very concise and only relays this single piece of information.
Jim Cramer highlights massive gains for Terns Pharmaceuticals shareholders
This article is a placeholder with very limited information. It indicates that Jim Cramer highlighted significant gains for Terns Pharmaceuticals shareholders. No further details about the gains or the company are provided in the content.
